From:  Engineering the microenvironment: advanced biomaterials for humanized in vitro immunotoxicology and carcinogenicity assessment

 Comparison of advanced in vitro models for toxicology assessment.

Model typePhysiological relevance
(ECM mimicry, cell-cell interactions, gradients, tissue architecture)
Throughput capability
(HTS compatibility)
Suitability for immunotoxicology
(immune cell integration)
Suitability for carcinogenicity
(TME mimicry, drug screening)
Key advantagesKey challenges
SpheroidsModerate: 3D cell-cell interactions, gradients, basic TME mimicry [37, 38].High: especially when using established cell lines [31, 36].Good: heterotypic spheroids can be co-cultured with immune cells [35, 52].Good: models drug resistance, TME mimicry, and proliferation effectively in a 3D context [37, 46].Simplicity, cost-effectiveness, scalability, HTS compatibility [31, 36].Lack of complex tissue architecture, limited long-term stability for primary cells, batch-to-batch size variability [8, 35].
OrganoidsHigh: self-organization creates organ-specific cell types, complex tissue architecture, and patient heterogeneity [32, 40].Moderate: significant variability in size and shape makes them less amenable to HTS than spheroids [57].Moderate: Some co-culture with immune cells is possible, but they often lack an autologous vascularized immune component [58].High: Patient-derived organoids (PDOs) allow for high-fidelity drug screening and capture the genetic landscape of the original tumor [9, 41].High human relevance, personalized medicine potential, recapitulates disease complexity [9, 32].High variability, standardization challenges, difficult integration with HTS, and a lack of a complete immune/stromal microenvironment [8, 57, 58].
Organ-on-Chip (OoC)/microphysiological systems (MPS)Very High: incorporates dynamic fluid flow, physiological mechanical forces, multi-cell co-cultures, and systemic effects [33, 60].Moderate to high: Throughput is improving with automation and standardized formats, but is not yet at traditional HTS levels [57].High: can simulate systemic effects and immune cell trafficking by connecting tissue compartments (e.g., tumor and lymph node) [51, 61].High: allows for dynamic TME emulation, multi-organ interactions (e.g., metabolism-toxicity), and advanced drug screening [33, 51].Mimics in vivo environment, uses human cells, allows real-time monitoring, enables multi-organ integration [33, 61].High cost, operational complexity, challenges in standardization and scale-up, complex data analysis [8].